Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC

What happened: Elicio Therapeutics (Nasdaq: ELTX) said it will host a virtual key opinion leader event on November 11, 2026, at 2:30 PM ET on camupepimut (ELI-002 7P) for metastatic and neoadjuvant PDAC. Key numbers: Event date November 11, 2026, 2:30 PM ET. AMPLIFY-7P Phase 2 enrolled 144 patients across 24 U.S. sites. Why it matters: The event will cover Phase 2 findings informing late-stage development strategy and expansion into neoadjuvant PDAC. AMPLIFY-7P did not meet its primary DFS endpoint, and new analyses are planned for ESMO Congress 2026. Market: -4.4% today ($1.52), -81.2% YTD — as of 00:00 UTC

Elicio Therapeutics (Nasdaq: ELTX) said it will host a virtual key opinion leader event on November 11, 2026, at 2:30 PM ET on camupepimut (ELI-002 7P) for metastatic and neoadjuvant PDAC.

The event will cover Phase 2 findings informing late-stage development strategy and expansion into neoadjuvant PDAC. AMPLIFY-7P did not meet its primary DFS endpoint, and new analyses are planned for ESMO Congress 2026. Market: -4.4% today ($1.52), -81.2% YTD — as of 00:00 UTC